耐碳青霉烯鲍曼不动杆菌研究进展  

Research advances in carbapnem-resistant Acinetobacter baumannii

作　　者：何翠娥[1] 胡志东[1] 

机构地区：[1]天津医科大学总医院医学检验科,300052

出　　处：《国际流行病学传染病学杂志》2012年第5期350-353,共4页International Journal of Epidemiology and Infectious Disease

摘　　要：随着抗菌药物的广泛应用，鲍曼不动杆菌已出现对氨基糖苷类、氟喹诺酮类、β-内酰胺类等药物耐药，碳青霉烯类抗生素被认为是目前临床治疗鲍曼不动杆菌最有效的药物之一，但近年来耐碳青霉烯类抗生素鲍曼不动杆菌比例逐年增长。此文将对耐碳青霉烯鲍曼不动杆菌的耐药现状、耐药机制及治疗进行综述。With the extensive use of antibiotics, Acinetobacter baumarmii has appeared resistant to aminoglyco- sides, fluoroquinolones, beta-lactams and other drugs. Carbapenem antibiotics is considered to be one of the most effec- tive drugs in clinical treatment of Ac/netobacter baumann/i, but carbapenem-resistant Acinetobacter baumannii is increasing gradually in recent years. This review is mainly about the resistant status, resistant mechanisms and treatment of car- bapenem-resistant Acinetobacter baumannii.

关 键 词：鲍氏不动杆菌 碳青霉烯类 耐药机制 耐药性 

分 类 号：R446.5[医药卫生—诊断学]